Amendments to the Specification:

Please insert the paper copy of the Sequence Listing filed herewith following the Drawings.

Please insert the following paragraph after the title:

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a National Stage of International Application No. PCT/US03/07323, filed March 7, 2003, which claims the benefit of priority from U.S. Provisional Application Serial No. 60/362,655, filed March 8, 2002.

Replace the paragraph beginning at page 5, line 23 with the following rewritten paragraph:

Fig. 8 is a representation of the nucleic acid sequence of MoMLV envelope protein (SEQ ID NO:4).

Replace the paragraph beginning at page 6, line 31 with the following rewritten paragraph:

Heterologous short peptide ligands suitable for use in the invention can also be identified using methods known in the art. Such methods include screening phage display in which a library of phage bearing a random selection of small peptides is selected for binding to the extracellular domain of a cell surface protein (i.e., a cell surface protein expressed on a host target cell). Nucleic acid sequences coding for such peptides are then cloned into wild-type envelope protein to produce chimeric envelope proteins. In another method using phage library, targeting to various organs can be achieved by injecting a phage display library into animals and identifying the peptides localized in each organ. This method has been successfully used to identify short peptides targeted to, e.g., kidney cells (CLPVASC, SEQ ID NO:3; ~~CLPVASC, SEQ ID NO:4;~~ and CGAREMC, SEQ ID NO:5) and to brain cells (CLSSRLDAC, SEQ ID

NO:6; WRCVLREGPAGGCAWFNRHRL; SEQ ID NO:7) (Pasqualini et al., 1996, Nature 380:364-366). Similarly, recombinant peptide libraries can also be screened for peptides that specifically bind to a protein that is expressed on a target host cell (Pasqualini *supra*; Wrighton et al., 1996, Science 273:458-464; Cwirla et al., 1997, Science 276:1696-1699; Arap et al., 1998, Science 279:377-380).

Replace the Table 1 beginning at page 17 with the following rewritten Table 1:

Table 1. Description of RGD viruses.

ENV #	Position of Ligand Insertion (A.A. Location)	# of Inserts	Deletion of Nucleotides in Env.
RGD_{13}[CAAA- GRGDSP-TRC] (SEQ ID NO:8)			
1	1	1X	
2	1	2X	
3	1	4X	
4	38	1X	
5	38	3X	
6	38	1X	5990-6082
7	68	1X	
8	68	2X	
9	68	1X	6082-6191
10	120	1X	
11	120	2X	6238-6281
12	120	3X	
13	185	1X	
14	230	1X	
15	230	2X	
16	235	1X	
17	235	4X	
18	310	1X	
19	310	2X	
20	321	1X	
21	321	2X	
22	382	1X	
23	382	2X	
24	382	3X	
25	388	1X	
26	388	2X	
RGD_{21}[CAAA- QGATFALRGDNPQG-TRC] (SEQ ID NO:11)			
1	1	1X	
2	38	1X	
3	38	1X	5990-6082
4	68	1X	
5	68	1X	6082-6191

6	120	1X	
R	120	1X	6238-6281
8	185	1X	
9	230	1X	
10	235	1X	
11	310	1X	
12	321	1X	
13	382	1X	
14	388	1X	
15	1,68	1X,1X	
16	1,230	1X,1X	

RGE_{21} [CAAA- QGATFALRGENPQG-TRC] (SEQ ID NO:25)

1	1	1X	
2	38	1X	5990-6082
3	68	1X	
4	68	1X	6082-1916
5	230	1X	

Replace the Table 2 beginning at page 24 with the following rewritten Table 2:

Table 2. Description of GRP and HRG viruses

ENV #	Position of Ligand Insertion (A.A. Location)	Deletion of Nucleotides in Envelope
GRP CAAA – **EQRLGNQWAVGHLM** – TRC (SEQ ID NO:18)		
GRP-1	1	
GRP-2	38	
GRP-3	38	5990-6082
GRP-4	68	
GRP-5	68	6082-1916
GRP-6	120	
GRP-7	120	6238-6281
GRP-8	185	
GRP-9	230	
GRP-10	235	
GRP-11	310	
GRP-12	321	
GRP-13	382	
GRP-14	388	

Del. 3 A.A.
|
FM D PSRY L M

HRG CAAA – **SHLVKCAEKEKTFCVNGGECYRVKTYGYLMCKCPNEFTGDRCQNYVIAS** – TRC (SEQ ID NO:26)

HRG-1	1	
HRG-2	38	
HRG-3	38	5990-6082
HRG-4	68	
HRG-5	68	6082-1916
HRG-6	120	
HRG-7	185	
HRG-8	230	
HRG-9	235	